CinRx’s Revolutionary Drug Deudomperidone (CIN-102) to be Showcased at 2023 Digestive Disease Week® Conference!

CinDome Pharma, a CinRx portfolio company, is excited to present a poster at the 2023 Digestive Disease Week (DDW) Conference in Chicago, Illinois. Titled “Effect of Therapeutic and Supratherapeutic Doses of Deudomperidone (CIN-102) on Cardiac Repolarization in a Thorough QT (TQT) Study In Healthy Subjects”, the poster will showcase the potential of deudomperidone to revolutionize the long-term management of gastroparesis. Attendees will have the opportunity to explore the exciting new findings and gain valuable insight into this promising treatment.

Gastroparesis is a condition that affects 16 million people in the US and is currently treated with metoclopramide, a treatment with a limited timeline and its own set of health risks. Fortunately, a new treatment option is on the horizon: deudomperidone, a modified formulation of domperidone that has been designed to address the challenges of domperidone and offer a safe, long-term solution to this previously unmet medical need.

Digestive Disease Week® (DDW) is the world’s premier event for gastroenterology, hepatology, endoscopy and gastrointestinal surgery professionals. Sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW 2023 will be held in-person and online from May 6-9.

This event brings together more than 3,100 groundbreaking abstracts and lectures that will reveal the latest breakthroughs in GI research, medicine and technology. Don’t miss out on this unique opportunity to stay at the forefront of the GI field!

About CinRx Pharma

CinRx is a revolutionary biotechnology platform that catapults promising new drugs from the lab to the patient faster than ever before. Our team of experts bring their deep scientific, clinical and operational know-how to the table, creating an optimal development trajectory with the goal of accelerating transformational new medicines to the people who need them most.

By leveraging our thoughtful portfolio model and dedicated funding mechanisms, we are creating a drug development superhighway that leads to success.

About CinDome Pharma

CinDome, a CinRx portfolio company, is on a mission to make a difference in the lives of the millions of people living with chronic gastroparesis. With an estimated 16 million adult patients in the US suffering from this debilitating condition, CinDome is working to develop an effective and well-tolerated treatment that can be taken on a chronic basis.

CinDome’s CIN-102, an engineered formulation of domperidone, is the first line treatment for gastroparesis worldwide and is currently not approved in the US. CinDome is dedicated to bridging this gap and providing much-needed relief for those living with gastroparesis.

Leave a Comment